Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biontech Se ADR (NQ: BNTX )

133.33 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 21, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 569
Open 133.33
Bid (Size) 133.11 (1)
Ask (Size) 134.01 (1)
Prev. Close 133.33
Today's Range 133.33 - 133.33
52wk Range 117.08 - 189.07
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Additional COVID-19 Booster Shots? Officials Anticipate FDA Authorization Within Few Weeks
The U.S. Food and Drug Administration is reportedly moving toward authorizing a second round of omicron-targeted COVID-19 booster shots for the elderly and other people at high risk. 
Via Benzinga
Covid Vaccine Battle Brewing: Moderna's Stephane Bancel Vs. Bernie Sanders
Moderna CEO Stephane Bancel will face a Senate Committee over pricing plans. 
Via Investor's Business Daily

Performance

YTD
-10.31%
-10.31%
1 Month
-3.05%
-3.05%
3 Month
-22.80%
-22.80%
6 Month
-0.10%
-0.10%
1 Year
-21.63%
-21.63%

More News

Read More
Where Did COVID-19 Really Originate? Biden Signs Bill To Declassify Origins Information
Via Benzinga
Moderna Wants To Charge About $130 Per COVID-19 Vaccine Dose
Via Benzinga
Price Over Earnings Overview: BioNTech
Via Benzinga
BioNTech Q4 2022 Earnings Conference Call On March 27, 2023 At 08:00 AM ET
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
Via Benzinga
BioNTech and OncoC4 Announce Strategic Collaboration to Co-Develop and Commercialize Novel Checkpoint Antibody in Multiple Solid Tumor Indications
From BioNTech SE
Via Globe NewsWire
7 Stocks Set to Soar When the Market Recovers
Via InvestorPlace
FDA Approves Pfizer/BioNTech's Bivalent COVID-19 Vaccine For Youngest Kids
Via Benzinga
Did Elon Musk Just Put His Skepticism Behind And Warm Up To mRNA Tech That Powers Most COVID-19 Vaccines?
Via Benzinga
BioNTech to Report Full Year and Fourth Quarter 2022 Financial Results and Operational Update on March 27, 2023
From BioNTech SE
Via Globe NewsWire
Wall Street Thinks These 2 Undervalued Stocks Have Exceptional Growth Potential
Via The Motley Fool
How Much Did US Government Spend On mRNA Vaccine Technology Before And During The Pandemic? The Number Can Be Surprising
Via Benzinga
European Commission Keeps Mum On Talks Regarding Pfizer COVID-19 Vaccine Contract: Report
Via Benzinga
BioNTech Announces Establishment of Interdisciplinary mRNA Excellence Center to Conduct Research Jointly with Scientists from Weizmann Institute of Science in Israel
From BioNTech SE
Via Globe NewsWire
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
Via Investor's Business Daily
Pfizer/BioNTech Seek Expanded Approval For Its Updated COVID-19 Shot As Primary Series Vaccination
Via Benzinga
Pharma Giant Pfizer Looks Strong for Investors, Despite COVID Sales Drop
Via The Motley Fool
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
Via Investor's Business Daily
Why Is Moderna (MRNA) Stock Down 5% Today?
Via InvestorPlace
Pfizer/BioNTech Get Ready For London Court Battle With Moderna Over COVID-19 Vaccine Patents
Via Benzinga
Is Novavax Stock a Buy With the New Normal for COVID?
Via The Motley Fool
The 3 Most Undervalued Growth Stocks for Your February Buy List
Via InvestorPlace
Better Buy: Novavax or BioNTech Stock?
Via The Motley Fool
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.